Clinical trials have complex eligibility criteria.Always talk to your clinician about you’re interest in participating in a trial.Learn why
HP Version - Clinical trials have complex eligibility criteria.Always talk to your clinician about you’re interest in participating in a trial.Learn why
Optimise reading forHealth ProfessionalsPatients
Closed (no longer recruiting)Last updated: 1 February 2024
Clinical summaryEligibilityParticipating hospitalsSupport
This is a trial in adult participants with unresectable, locally advanced, Stage III non-small cell lung cancer (NSCLC) treated with pembrolizumab in combination with platinum doublet chemotherapy and standard thoracic radiotherapy followed by pembrolizumab monotherapy.
This trial is treating patients with Stage III non-small cell lung cancer.
Lung cancer
18+
II
KEYNOTE-799
Use the hyperlinks, where available to access additional clinical trial information.
Merck
A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC (KEYNOTE-799)
Lung
Share with email
Print this page
Download brochure
Clinical trials have complex eligibility criteria.
Ask your doctor if this trial could be right for you.
+ Show non-recruiting hospitals
Tell us if you find this trial availability is not accurate.Report inaccuracy
Speak with someone who has cancer clinical trial experience.
Learn more
If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council’s experienced cancer nurses on 131120.
When you are considering a cancer clinical trial, it is a good idea to discuss it with your family, friends or carers.
Thank you for helping us to increase accuracy of the trial. Our team will validate the information and update the information as soon as possible.